AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024 AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa USH1B

AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting

AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B